Global Naftopidil Tablets Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Naftopidil Tablets Market Research Report 2024
Naftopidil is an α-receptor antagonist, which can relieve the sympathetic tension of the prostate and urethra by blocking adrenaline α1 receptors, reduce urethral pressure, and improve urination disorders caused by benign prostatic hyperplasia, etc. symptom.
According to QYResearch’s new survey, global Naftopidil Tablets market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Naftopidil Tablets market research.
Key manufacturers engaged in the Naftopidil Tablets industry include Asahi Kasei Corporation, Beijing SL Pharmaceutical Co.,Ltd., Hubei Qianjiang Pharmaceutical Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., Hainan Simcere Pharmaceutical Co., Ltd., Bengbu Fengyuan Pharmaceutical Co., Ltd., GUIZHOU-EAKAN Pharmaceutical Co., Ltd., Tonghua Jitong Medical Co., Ltd. and Nanjing Meirui Pharma Co., Ltd., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Naftopidil Tablets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Naftopidil Tablets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Naftopidil Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Asahi Kasei Corporation
Beijing SL Pharmaceutical Co.,Ltd.
Hubei Qianjiang Pharmaceutical Co., Ltd.
Shanghai Shyndec Pharmaceutical Co., Ltd.
Hainan Simcere Pharmaceutical Co., Ltd.
Bengbu Fengyuan Pharmaceutical Co., Ltd.
GUIZHOU-EAKAN Pharmaceutical Co., Ltd.
Tonghua Jitong Medical Co., Ltd.
Nanjing Meirui Pharma Co., Ltd.
Shenzhen Neptunus Pharmaceutical Co., Ltd.
Segment by Type
25mg/tablet
50mg/tablet
Hospital
Retail Pharmacy
Clinic
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Naftopidil Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to QYResearch’s new survey, global Naftopidil Tablets market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Naftopidil Tablets market research.
Key manufacturers engaged in the Naftopidil Tablets industry include Asahi Kasei Corporation, Beijing SL Pharmaceutical Co.,Ltd., Hubei Qianjiang Pharmaceutical Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., Hainan Simcere Pharmaceutical Co., Ltd., Bengbu Fengyuan Pharmaceutical Co., Ltd., GUIZHOU-EAKAN Pharmaceutical Co., Ltd., Tonghua Jitong Medical Co., Ltd. and Nanjing Meirui Pharma Co., Ltd., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Naftopidil Tablets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Naftopidil Tablets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Naftopidil Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Asahi Kasei Corporation
Beijing SL Pharmaceutical Co.,Ltd.
Hubei Qianjiang Pharmaceutical Co., Ltd.
Shanghai Shyndec Pharmaceutical Co., Ltd.
Hainan Simcere Pharmaceutical Co., Ltd.
Bengbu Fengyuan Pharmaceutical Co., Ltd.
GUIZHOU-EAKAN Pharmaceutical Co., Ltd.
Tonghua Jitong Medical Co., Ltd.
Nanjing Meirui Pharma Co., Ltd.
Shenzhen Neptunus Pharmaceutical Co., Ltd.
Segment by Type
25mg/tablet
50mg/tablet
Segment by Application
Hospital
Retail Pharmacy
Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Naftopidil Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source